StockData
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. (MAIA) company profile

MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$1.25+0.24 (+23.76%)

Close on Nov 17, 2026Market cap $76.03MP/E –Yield –

About MAIA Biotechnology

Pharmaceutical Preparations, SIC 2834

MAIA Biotechnology, Inc. is a clinical-stage biotechnology entity engaged in the research, development, and advancement of targeted oncology treatments. The enterprise primarily focuses on investigational therapies targeting telomeres and cancer cell processes to combat complex malignancies. Its therapeutic pipeline includes clinical and technological development centered on THIO (ateganosine), aimed at addressing severe oncological conditions for patients with advanced cancers. The enterprise coordinates research activities alongside collaboration and licensing agreements established with research institutions and industry partners.

The organization conducts administrative, research, and regulatory activities with domestic jurisdictions in the United States as well as foreign authorities, such as the Australian Taxation Office. MAIA Biotechnology, Inc. maintains its principal executive offices in Chicago, Illinois.

Summary of the business section of MAIA Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
MAIA Biotechnology, Inc.
Founded
2018
Headquarters
Chicago, IL
Address
444 West Lake Street, Suite 1700 60606
Phone
(312) 416-8592
Employees
13, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Charlotte, North Carolina

Stock & identifiers

Ticker
MAIA
Exchange
NYSE
IPO date
Jul 29, 2022
Shares outstanding
61M, Aug 10, 2026
Public float
$48.95M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1878313
CUSIP
552641102
ISIN
US5526411021
FIGI
BBG0113Q7J88
Share class FIGI
BBG0113Q7J97
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Vlad VitocChief Executive Officer, Director1,359,221
Sergei GryaznovChief Scientific Officer46,511
Jeffrey C. HimmelreichHead of Finance–
Stan SmithDirector1,619,178
Ramiro GuerreroDirector773,296
Cristian LuputDirector437,628
Jean-Manasse TheageneDirector–
Ngar Yee LouieDirector1,248,888
Steven M. ChaoukiDirector151,873

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Vlad Vitoc
Chief Executive Officer and President
$612.33K$334.81K$1.12M$13.01K$2.08M+53%
Jeffrey C. Himmelreich
Head of Finance
$272.92K$68.23K$69.60K$10.24K$420.99K+24%
Sergei Gryaznov
Chief Scientific Officer
$478.50K$213.81K$562.24K$12.74K$1.27M+36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 29, 2022
Offer price
$5.00
Securities offered
2,000,000
Gross proceeds
$10.00M
Exchange
NYSE American
First trading day
Jul 28, 2022
First-day close
$4.46-10.8%
Lock-up ends (est.)
Jan 24, 2023

“We are offering 2,000,000 shares of our common stock at an initial public offering price of $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of December 31, 2025, we had a total of 13 full-time employees which includes one employee employed by our Romanian subsidiary.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?